The CJC-1295/ipamorelin combination is the single most widely used research peptide stack in the fitness and longevity community. It's talked about constantly on r/Peptides, r/PeptideGuidance, and across every major peptide vendor's product page. Protocols are freely shared. Vendor guides are abundant.
And yet there's a foundational confusion baked into almost all of that content — a confusion that means a significant number of people using this stack may be using a completely different compound than they think, on the wrong dosing schedule, getting meaningfully different effects than they intended.
The confusion is this: CJC-1295 and CJC-1295 with DAC are not the same compound. They have different molecular structures, different half-lives (30 minutes vs. 8 days), different dosing protocols, and different physiological effects. Vendors frequently label one as the other, or simply as "CJC-1295" with no further specification. And without proper analytical testing, you have no way to know which one is actually in your vial.
This article covers the full harm reduction picture for the GH secretagogue stack: what the two forms of CJC-1295 actually are and why the distinction matters, how ipamorelin compares to other GHRPs and what "clean" actually means, why injection timing has more impact than most protocol guides acknowledge, what the documented severe adverse reaction case tells us about stacking risk, and how to verify what you're actually injecting.
Harm reduction note: This is informational content, not medical advice. Research peptides are not approved for human use. Regulatory status for CJC-1295 and ipamorelin under WADA and FDA is covered below — read it before using these compounds competitively or medicinally.
CJC-1295 Without DAC vs. CJC-1295 With DAC: The Distinction That Changes Everything
This is the foundational piece of information that a surprising number of experienced stack users don't have clearly.
CJC-1295 (no DAC) — also called Mod GRF 1-29 by researchers to avoid exactly this confusion — is a modified version of the first 29 amino acids of growth hormone releasing hormone (GHRH). It stimulates the pituitary gland to release GH in a pulse. Its biological half-life in the body is approximately 30 minutes. You inject it, GH releases, and the compound is largely cleared within an hour or two.
CJC-1295 WITH DAC — the DAC stands for Drug Affinity Complex, a chemical modification that binds the peptide to serum albumin in the bloodstream. This dramatically extends its half-life to approximately 6–8 days. A single injection of CJC-1295 with DAC continues stimulating pituitary GH release for most of a week.
These are not interchangeable. The protocols for them are opposite:
| CJC-1295 (no DAC) | CJC-1295 with DAC | |
|---|---|---|
| Half-life | ~30 minutes | ~6–8 days |
| Injection frequency | 2–3x daily with GHRP | Once or twice weekly |
| GH release pattern | Pulsatile (mimics natural) | Sustained elevation |
| Stack timing | Simultaneously with ipamorelin | Independent of GHRP timing |
| Typical dose | 100–200mcg per injection | 1000–2000mcg per week |
If you're running a protocol designed for CJC-1295 (no DAC) — three injections daily, 100mcg each, timed with ipamorelin — and your vial actually contains CJC-1295 with DAC, you've injected three large doses of a compound that will stimulate GH release continuously for a week. That's a very different physiological event than what you intended. The reverse creates the opposite problem: a CJC-1295 with DAC protocol applied to the no-DAC form will deliver minimal effect because the compound clears before the next injection.
Why this confusion is widespread: Many vendors simply label their product as "CJC-1295" and reference protocols that could apply to either form. Some vendor guides specifically recommend the high-frequency pulsing protocol (correct for no-DAC) for a product that may contain the DAC form, or vice versa. Without mass spectrometry confirmation of the molecular weight, you cannot know which you have.
The molecular weight difference is detectable: CJC-1295 (no DAC) has a molecular weight of approximately 3367 Da; CJC-1295 with DAC is approximately 3647 Da. A proper COA with mass spectrometry will show you which you have. A purity-only COA will not. This is one of the most concrete practical reasons the COA verification framework in the first article of this series matters for this specific stack — the document needs mass spec to tell you which molecule you bought.
Ipamorelin: What "Clean" Actually Means (and Doesn't)
Ipamorelin is a growth hormone releasing peptide (GHRP) — a category of compounds that stimulate GH release through a different mechanism than GHRH peptides like CJC-1295. GHRPs work primarily through the ghrelin receptor. The combination of a GHRH analog (CJC-1295) and a GHRP (ipamorelin) produces a synergistic GH pulse that's larger than either compound alone.
Ipamorelin is consistently described in community content as "the cleanest GHRP." This framing is partially accurate and partially overstated.
What's accurate: Compared to other GHRPs — particularly GHRP-2 and GHRP-6 — ipamorelin produces a more selective GH pulse with less elevation of cortisol and prolactin. GHRP-6, the most ghrelin-receptor-active of the common GHRPs, causes significant hunger stimulation (because ghrelin is the hunger hormone) and measurable cortisol elevation. GHRP-2 is more potent for GH release but also causes greater cortisol and prolactin spikes. By comparison, ipamorelin at standard doses (200–300mcg) causes relatively modest cortisol elevation and minimal prolactin response.
What "clean" doesn't mean: At higher doses — above 500mcg — ipamorelin's selectivity advantage narrows. Cortisol response increases in a dose-dependent way. The "no cortisol spike" claim that circulates in community content is accurate at standard doses and overstated at high doses.
Ipamorelin also still stimulates hunger via ghrelin receptors, just less aggressively than GHRP-6. If you're using this stack for body composition and noticing increased appetite, that's pharmacological, not psychological.
GHRP comparison at a glance:
| GHRP | GH release | Cortisol | Prolactin | Hunger |
|---|---|---|---|---|
| Ipamorelin | Moderate-high | Low (at std dose) | Low | Mild |
| GHRP-2 | High | Moderate | Moderate | Moderate |
| GHRP-6 | High | Moderate | Low-moderate | Strong |
The "clean" framing for ipamorelin is real and justifies its popularity. It just isn't unconditional.
Why Injection Timing Is More Important Than Most Protocols Acknowledge
Here's the mechanism point that most vendor protocol guides either don't include or bury in a footnote: insulin suppresses GH release.
When you eat carbohydrates, insulin rises. Elevated insulin levels blunt the GH pulse that CJC-1295/ipamorelin would otherwise stimulate. The peptides can work, but the effect is substantially reduced when injected into a high-insulin environment.
This is why the community-standard advice of injecting at bedtime, on an empty stomach (at least 1.5–2 hours post-meal), is physiologically sound — not just tradition. The nighttime fasting state provides the lowest-insulin window of the day, and it happens to coincide with the largest natural GH pulse (the one that occurs in the first few hours of deep sleep). Stacking the peptide-induced GH pulse with the natural nocturnal pulse amplifies the effect.
What this means practically:
- Post-workout injection: potentially high-insulin environment if you consumed carbohydrates peri-workout. Less effective than commonly thought.
- Morning fasted injection: reasonable, but the GH response may still be blunted by dawn cortisol elevation.
- Pre-sleep injection (2+ hours post last meal): optimal for most users based on the pharmacology.
If you've been injecting CJC-1295/ipamorelin 30 minutes after dinner and not seeing expected results, the timing is the most likely variable to examine before adjusting the dose.
The glucose tolerance angle: GH itself transiently raises blood glucose (GH is counter-regulatory to insulin). Stacking GH-stimulating peptides with a diet that already stresses glucose tolerance could theoretically amplify that effect. For most healthy users at standard doses this isn't a significant concern — the GH pulses are physiological, not pharmacological in magnitude. But it's worth being aware of if you have any metabolic concerns.
The Documented Anaphylaxis Case: What It Actually Tells Us
In the research for this series, one of the most significant adverse event cases in community documentation involves a severe reaction to a CJC-1295/ipamorelin stack — specifically, a case in which a user experienced a heart rate exceeding 160 bpm and was hospitalized after injecting what they believed was a standard dose.
This case is significant because it illustrates the single biggest safety unknown in the peptide stacking space: when something goes wrong with an injectable gray-market compound, you cannot know what went wrong.
Possible explanations for a severe reaction like this include:
- Endotoxin contamination — a batch of compounded peptide with elevated lipopolysaccharide (bacterial endotoxin) levels can cause fever, tachycardia, and systemic inflammatory response that looks like anaphylaxis but is a pyrogen reaction. This is the most common explanation for severe reactions that appear with a new batch and resolve completely after stopping.
- Allergic/anaphylactic response to the compound or excipient — true IgE-mediated anaphylaxis to ipamorelin or a carrier substance (commonly mannitol or acetic acid in peptide preparations). Presents with tachycardia, urticaria, bronchospasm.
- Pharmacological GH overstimulation — at very high doses, acute GH elevation can cause transient fluid retention and cardiovascular effects. Less likely at standard community doses.
- Reaction to an adulterant or impurity — if the COA was not verified or the product was from a low-quality source, the reaction may have had nothing to do with CJC-1295 or ipamorelin.
The documented hospitalization case resolved. The user survived. But the inability to determine the exact cause — without a verified COA and without having sent a sample of the vial used to an independent laboratory — means the community can't learn the right lesson from it. It becomes a data point that gets attributed to the compound itself when the actual cause may have been contamination from a specific batch.
This is the intersection of the COA framework and stacking safety: your ability to evaluate what went wrong is zero if you don't know what you injected. Independent testing before use, not after an incident, is the only way to generate meaningful safety data.
Receptor Desensitization and Why Cycles Matter
GHRPs work through the ghrelin receptor (GHS-R1a). Continuous, uninterrupted activation of this receptor leads to downregulation — the receptor becomes less sensitive to stimulation, and the GH response to the same dose diminishes over time.
This is why experienced users cycle these compounds. The commonly cited 5-days-on/2-days-off protocol exists specifically to allow partial receptor resensitization on the off days. Continuous daily use for weeks on end without cycling will produce diminishing returns.
For CJC-1295 with DAC, this creates a specific complication: the compound's 6–8 day half-life means that even if you stop injecting, the receptor stimulation continues for most of a week. Cycling the GHRH component is functionally difficult with the DAC form. This is one reason some experienced users prefer CJC-1295 without DAC — the short half-life allows genuine cycling of both components.
Longer-term breaks (4–8 weeks off between cycles) are commonly recommended and physiologically logical for restoring full receptor sensitivity.
WADA Status and Regulatory Reality
CJC-1295 and ipamorelin — and all GHRPs and GHRH analogs — are prohibited under WADA Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.
S2 is a different classification from BPC-157's S0 (which is prohibited simply for being unapproved). S2 classification means WADA has specifically identified these compounds as performance-enhancing. The S2 ban applies to all GH secretagogues: CJC-1295 (both forms), ipamorelin, GHRP-2, GHRP-6, and all related compounds.
As covered in the BPC-157 article earlier in this series, the WADA ban applies to amateur and masters-level competitors in sports with WADA-aligned testing — not just professional athletes. CrossFit, powerlifting, masters track, cycling, and many other organized sports are within WADA's testing framework.
Under FDA rules, CJC-1295 and ipamorelin are not approved for human use and are not on the compounding-permitted list. They exist in the same gray-market research chemical framework as BPC-157 and other peptides. There is no prescription pathway for these compounds in the US.
The Harm Reduction Summary
Here is the complete picture for someone using or considering the CJC-1295/ipamorelin stack:
Know which CJC-1295 you have. Demand mass spectrometry confirmation on your COA. The molecular weight will tell you whether you have the DAC or non-DAC form. Use the COA verification checklist from the first article in this series — purity-only documentation is not sufficient for a compound where the form matters this much.
Match your protocol to your compound. CJC-1295 (no DAC): multiple daily pulses, co-administered with ipamorelin. CJC-1295 with DAC: once or twice weekly, separate from ipamorelin timing.
Time your injections. Inject in a fasted state, ideally at bedtime, minimum 1.5–2 hours after the last meal. High-insulin environments suppress the GH response the stack is designed to produce.
Ipamorelin dose discipline. Standard doses (100–300mcg per injection) maintain the compound's selective profile. Higher doses bring you closer to the cortisol elevation profile of less selective GHRPs.
Cycle the stack. 5-on/2-off at minimum; 8–12 week cycles with off periods of equal or greater length for receptor resensitization.
WADA: Prohibited under S2 for any athlete subject to WADA-aligned testing. This is not ambiguous.
Tools and Resources
PeptideGuard — harm-reduction AI for research peptides. Useful for evaluating your specific stack configuration, checking compound interactions, interpreting COA documentation, and understanding what the research actually says versus what vendor guides claim. Particularly useful for navigating the CJC-1295 with/without DAC question when vendor documentation is ambiguous.
COA Verification Guide — how to evaluate the documentation from your vendor, confirm mass spectrometry is present, check endotoxin testing, and verify your COA is actually specific to your lot number. Essential before using any injectable peptide.
BPC-157 Regulatory Status — covers the WADA framework in depth, including how S0 and S2 differ and how competition drug testing actually works for amateur athletes. Context that applies to the GH secretagogue stack.
Semaglutide Compounding Status — some users stack GLP-1 agents with GH secretagogues for body composition. The legal landscape for compounded GLP-1s is covered in full here.
Janoshik Analytical (janoshik.com) — independent third-party testing. If you want to confirm which form of CJC-1295 you have, Janoshik offers mass spectrometry that will resolve the molecular weight question definitively.
PubMed — search "CJC-1295 growth hormone," "ipamorelin ghrelin receptor," and "GHRP cortisol" for the underlying science. The receptor biology, timing research, and pulsatile GH literature is available and worth reading before relying solely on community-sourced protocols.
What's Next
The PCAC advisory committee meets July 23–24, 2026. BPC-157 is on the agenda for July 23. Depending on the committee's recommendation, that outcome could shift the regulatory landscape for the most popular research peptide in the community. Coverage will run here within 48 hours of the recommendations being published.
The next article in this series covers TB-500 (thymosin beta-4) — a compound with a different mechanism than BPC-157 but often used in the same stacks, with its own distinct regulatory status after the April 2026 reclassification, and a set of safety questions that community coverage consistently gets wrong.
This article is for harm-reduction and informational purposes only. Research peptides are not approved for human use by the FDA. This is not medical or legal advice. Regulatory and WADA status is subject to change — verify with primary sources before making decisions.
